JPH0150226B2 - - Google Patents

Info

Publication number
JPH0150226B2
JPH0150226B2 JP57037411A JP3741182A JPH0150226B2 JP H0150226 B2 JPH0150226 B2 JP H0150226B2 JP 57037411 A JP57037411 A JP 57037411A JP 3741182 A JP3741182 A JP 3741182A JP H0150226 B2 JPH0150226 B2 JP H0150226B2
Authority
JP
Japan
Prior art keywords
starch
gasn
sodium
solvent
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP57037411A
Other languages
English (en)
Japanese (ja)
Other versions
JPS58154548A (ja
Inventor
Masanobu Kawamata
Koichi Ushimaru
Hiroyuki Goshi
Hidemoto Myasako
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Priority to JP57037411A priority Critical patent/JPS58154548A/ja
Priority to DE8383102097T priority patent/DE3361520D1/de
Priority to EP83102097A priority patent/EP0088958B1/en
Priority to KR1019830000949A priority patent/KR900003452B1/ko
Priority to US06/473,452 priority patent/US4533552A/en
Publication of JPS58154548A publication Critical patent/JPS58154548A/ja
Publication of JPH0150226B2 publication Critical patent/JPH0150226B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/04—Sodium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
JP57037411A 1982-03-09 1982-03-09 アズレン誘導体の安定化方法 Granted JPS58154548A (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP57037411A JPS58154548A (ja) 1982-03-09 1982-03-09 アズレン誘導体の安定化方法
DE8383102097T DE3361520D1 (de) 1982-03-09 1983-03-03 Stabilization of azulene derivatives
EP83102097A EP0088958B1 (en) 1982-03-09 1983-03-03 Stabilization of azulene derivatives
KR1019830000949A KR900003452B1 (ko) 1982-03-09 1983-03-09 아줄렌 유도체의 안정화 방법
US06/473,452 US4533552A (en) 1982-03-09 1983-05-11 Stabilization of azulene derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57037411A JPS58154548A (ja) 1982-03-09 1982-03-09 アズレン誘導体の安定化方法

Publications (2)

Publication Number Publication Date
JPS58154548A JPS58154548A (ja) 1983-09-14
JPH0150226B2 true JPH0150226B2 (enExample) 1989-10-27

Family

ID=12496774

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57037411A Granted JPS58154548A (ja) 1982-03-09 1982-03-09 アズレン誘導体の安定化方法

Country Status (5)

Country Link
US (1) US4533552A (enExample)
EP (1) EP0088958B1 (enExample)
JP (1) JPS58154548A (enExample)
KR (1) KR900003452B1 (enExample)
DE (1) DE3361520D1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1201383A (en) * 1983-11-18 1986-03-04 Warner-Lambert Canada Inc. Antacid composition and process for its preparation
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6024090A (en) 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US7448375B2 (en) 1993-01-29 2008-11-11 Aradigm Corporation Method of treating diabetes mellitus in a patient
JPH10501519A (ja) 1994-03-07 1998-02-10 インヘイル・セラピューティック・システムズ インシュリンを肺に送給できる方法および組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1034327B (de) * 1957-08-30 1958-07-17 Chemiewerk Homburg Ag Verfahren zur Herstellung stabiler Praeparate, wie Puder, Tabletten, Dragees u. dgl., mit einem Gehalt an guajazulensulfo-sauren Salzen
US3833757A (en) * 1972-04-10 1974-09-03 Computer Television Inc Electronic bilateral communication system for commercial and supplementary video and digital signaling
JPS5630927A (en) * 1979-08-24 1981-03-28 Zeria Shinyaku Kogyo Kk Stabilization of guaiazulene and its derivative
DE3173600D1 (en) * 1980-05-20 1986-03-13 Mallinckrodt Inc Spray dried n-acetyl-p-aminophenol compositions and method for manufacture thereof
JPS57108012A (en) * 1980-12-25 1982-07-05 Ota Seiyaku Kk Preparation of pharmaceutical preparation containing sodium azulenesulfonate
US4395422A (en) * 1981-04-06 1983-07-26 Basf Wyandotte Corporation Spray dried vitamin E powder

Also Published As

Publication number Publication date
EP0088958A1 (en) 1983-09-21
KR840004121A (ko) 1984-10-06
US4533552A (en) 1985-08-06
JPS58154548A (ja) 1983-09-14
EP0088958B1 (en) 1985-12-18
KR900003452B1 (ko) 1990-05-19
DE3361520D1 (de) 1986-01-30

Similar Documents

Publication Publication Date Title
CA2056066C (en) A physical form of n-[4-[5-(cyclopentyloxycarbony)amino-1-methylindol-3yl-methy1]-3-methoxybenzoy1]-2-methlbenzenesulphonamide, processes for its preparation and compositions containing it
US4113882A (en) Stabilized oral prostaglandin formulation and the process for the preparation thereof
US4699927A (en) Anticonvulsant valproic acid salts
JPH0150226B2 (enExample)
JP2002505328A (ja) 抗潰瘍医薬の硝酸塩
JP2002505276A (ja) 潰瘍用医薬組成物
CA1077502A (en) Microcrystalline 3-(alpha-acetonylbenzyl)-4-hydroxycoumarin (warfarin) compositions thereof methods of making and using
US4066787A (en) Stabilized prostaglandin composition and the process for the preparation thereof
JPH0150225B2 (enExample)
JPS60255737A (ja) ジヒドロピリジン調製物
JPH0548234B2 (enExample)
JPS60255725A (ja) ジヒドロピリジン配合調製物
CA1169867A (en) Oxazole derivatives
JPH0249720A (ja) 難溶性薬剤組成物
JPS5836960B2 (ja) １−β−Ｄ−リボフラノシル−１．２．４−トリアゾ−ル−３−カルボキシアミドの製法
US4222939A (en) Process for preparing solid sodium amoxycillin
EP0413299A1 (en) Antibiotic composition
AU3095600A (en) New pharmaceutical formulation
WO2007058634B1 (en) Stable formulation of amorphous perindopril salts, a process for their preparation, especially industrial preparation, and their use in the therapy of hypertension
JPH0222225A (ja) 胃酸分泌抑制剤含有固型製剤
JPS60255736A (ja) ニフエジピン調製物
JP2773895B2 (ja) ダナゾール組成物
JPS60255724A (ja) ニフエジピン配合調製物
JP3485941B2 (ja) アズレン誘導体の安定な製剤およびその製造方法
JPH0250086B2 (enExample)